Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VERITAC-3
2022-500545-24-00Phase 3Authorised
- Sponsor
- Pfizer
- Start
- Oct 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial in breast cancer comparing PF-07850327 + palbociclib with letrozole + palbociclib (2 arms). Primary endpoints: Incidence of Grade 4 neutropenia adverse events within first 4 cycles, Incidence of dose reduction or drug discontinuation within first 4 cycles and 1 more. Planned start Oct 2023; status: authorised.
02
Drugs
vepdegestrantpalbociclibletrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2022-500545-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500545-24-00.